Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
|
|
Axonics, Inc. (AXNX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/21/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/27/2023 |
8-K
| Quarterly results |
| 05/18/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/01/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob... |
| 03/01/2023 |
8-K
| Quarterly results |
| 01/11/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 10/31/2022 |
8-K
| Quarterly results |
| 08/05/2022 |
8-K
| Quarterly results |
| 08/01/2022 |
8-K
| Quarterly results |
| 06/01/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 03/07/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/24/2022 |
8-K
| Quarterly results |
| 01/06/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 11/04/2021 |
8-K
| Quarterly results |
| 08/05/2021 |
8-K
| Quarterly results |
| 07/19/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/25/2021 |
8-K
| Quarterly results |
| 06/21/2021 |
8-K
| Quarterly results |
| 05/14/2021 |
8-K
| Quarterly results |
| 05/06/2021 |
8-K
| Quarterly results |
| 05/05/2021 |
8-K
| Quarterly results |
| 04/01/2021 |
8-K
| Quarterly results |
| 03/02/2021 |
8-K
| Quarterly results |
| 02/25/2021 |
8-K
| Quarterly results |
| 01/25/2021 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 12/14/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/04/2020 |
8-K
| Quarterly results |
| 08/06/2020 |
8-K
| Quarterly results |
| 07/13/2020 |
8-K
| Quarterly results |
| 06/26/2020 |
8-K
| Quarterly results |
| 05/12/2020 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Underwriting Agreement, by and among Axonics Modulation Technologies, Inc. and BofA Securities, Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC",
"Opinion of K&L Gates LLP",
"Axonics® Announces Proposed Public Offering of Common Stock IRVINE, Calif – May 7, 2020 – Axonics Modulation Technologies, Inc. , a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation devices for the treatment of urinary and bowel dysfunction, today announced that it has commenced a proposed public offering of $100,000,000 in shares of its common stock. Axonics expects to grant the underwriters a 30-day option to purchase up to $15,000,000 in additional shares of its common stock at the public offering price, less the underwriting discount. Axonics anticipates using net proceeds from the offering to support the commercialization of its r-SNM System in the United States, Europe and Canada, to conduct SNM-related research and developm...",
"Axonics® Announces Pricing of Public Offering of Common Stock IRVINE, Calif – May 7, 2020 – Axonics Modulation Technologies, Inc. , a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation devices for the treatment of bladder and bowel dysfunction, today announced the pricing of its public offering of 4,000,000 shares of its common stock at a public offering price of $32.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering to Axonics, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $130 million. In addition, the underwriters have a 30-day option to purchase up to an additional 600,000 shares of common stock from Axonics...",
"Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock IRVINE, Calif – May 12, 2020 – Axonics Modulation Technologies, Inc. , a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation devices for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 4,600,000 shares of common stock at the public offering price of $32.50 per share, which includes the shares purchased pursuant to the exercise in full of the underwriters’ option to purchase up to an additional 600,000 shares of its common stock. The gross proceeds from the offering to Axonics, before deducting underwriting discounts and commissions and estimated ..." |
|
|
|
|